Nubeqa with androgen deprivation therapy reduces radiological progression risk by 46% and death risk by 19% in metastatic hormone-sensitive prostate cancer. Nurses are essential in educating patients ...
Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results